載入中
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
前收盤價
US$8.87
+US$0.12 · +1.37%
盤中時間採用ET。市場資料可能有所延遲。
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
日內區間
目前US$8.87
52週區間
目前US$8.87
盤中時間採用ET。市場資料可能有所延遲。
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
日內區間
目前US$8.87
52週區間
目前US$8.87
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Simplify Health Care ETFPINK968.65萬3.04%3.19億 USD0.51%US$38.527+2.57%
Vanguard Morningstar Total Stock Market ETFVTI790.49萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM477.09萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF353.46萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO148.89萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC58.46萬0.04%13.17億 USD0.60%US$183+0.11%
Global X - Genomics & Biotechnology ETFGNOM22.78萬0.21%1.04億 USD0.50%US$68.75+4.44%
Vanguard Russell 2000 Value ETFVTWV22.64萬0.02%14億 USD0.06%US$185.81-0.13%Simplify Health Care ETFPINKVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGlobal X - Genomics & Biotechnology ETFGNOMVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
